Centiva Capital LP Acquires 8,734 Shares of Teleflex Incorporated (NYSE:TFX)

Centiva Capital LP increased its holdings in shares of Teleflex Incorporated (NYSE:TFX - Free Report) by 186.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 13,412 shares of the medical technology company's stock after buying an additional 8,734 shares during the quarter. Centiva Capital LP's holdings in Teleflex were worth $2,387,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. CANADA LIFE ASSURANCE Co boosted its stake in shares of Teleflex by 0.4% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 20,320 shares of the medical technology company's stock valued at $3,614,000 after purchasing an additional 74 shares in the last quarter. Hengehold Capital Management LLC grew its stake in shares of Teleflex by 7.3% during the fourth quarter. Hengehold Capital Management LLC now owns 1,289 shares of the medical technology company's stock worth $229,000 after buying an additional 88 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Teleflex by 38.2% during the fourth quarter. Exchange Traded Concepts LLC now owns 340 shares of the medical technology company's stock worth $61,000 after buying an additional 94 shares in the last quarter. Isthmus Partners LLC lifted its stake in shares of Teleflex by 7.3% in the 4th quarter. Isthmus Partners LLC now owns 1,535 shares of the medical technology company's stock valued at $273,000 after acquiring an additional 105 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Teleflex by 2.4% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 4,991 shares of the medical technology company's stock valued at $888,000 after acquiring an additional 118 shares in the last quarter. 95.62% of the stock is owned by institutional investors and hedge funds.

Teleflex Price Performance

TFX stock opened at $120.89 on Wednesday. Teleflex Incorporated has a 1 year low of $120.06 and a 1 year high of $249.91. The stock has a market capitalization of $5.61 billion, a PE ratio of 24.03, a price-to-earnings-growth ratio of 1.73 and a beta of 1.17. The company's 50-day moving average is $134.36 and its 200-day moving average is $168.73. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39.

Teleflex (NYSE:TFX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.88 by $0.03. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The firm had revenue of $700.67 million during the quarter, compared to the consensus estimate of $699.37 million. During the same quarter in the previous year, the company posted $3.21 earnings per share. The company's quarterly revenue was down 5.0% on a year-over-year basis. Equities research analysts expect that Teleflex Incorporated will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 17th. Shareholders of record on Friday, March 7th were paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.12%. The ex-dividend date was Friday, March 7th. Teleflex's dividend payout ratio (DPR) is 42.90%.

Analyst Ratings Changes

Several research firms have commented on TFX. Royal Bank of Canada dropped their target price on Teleflex from $150.00 to $145.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Raymond James lowered Teleflex from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. StockNews.com downgraded Teleflex from a "buy" rating to a "hold" rating in a research report on Friday, February 28th. Mizuho set a $155.00 price target on shares of Teleflex in a report on Wednesday, April 16th. Finally, Piper Sandler reissued a "neutral" rating and set a $140.00 target price (down previously from $255.00) on shares of Teleflex in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $164.63.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.